Skip to main
RLYB
RLYB logo

Rallybio Corp (RLYB) Stock Forecast & Price Target

Rallybio Corp (RLYB) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Rallybio Corp's RLYB212 has demonstrated promising Phase 1b proof-of-concept data, indicating its potential to effectively prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a severe condition lacking FDA-approved treatment options. The recent dosing of the first pregnant woman at high risk for FNAIT marks a significant milestone, underscoring the therapy's clinical potential and the company's commitment to addressing urgent healthcare needs. Additionally, the company has not modeled other pipeline programs, suggesting potential upside to its valuation that could further enhance its market position.

Bears say

Rallybio Corp reported a net loss of $0.25 per share, which underscores ongoing financial challenges facing the company as it seeks to advance its clinical programs. There are significant risks associated with potential delays in clinical trials for key pipeline candidates and the failure to generate positive clinical data, specifically for RLYB212 in fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116 in paroxysmal nocturnal hemoglobinuria (PNH). Additionally, partnership risks with entities such as Swedish Orphan Biovitrum AB, Exscientia PLC, and Sanofi S.A., along with long-term dilution risks, further contribute to a negative outlook for Rallybio's stock.

Rallybio Corp (RLYB) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rallybio Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rallybio Corp (RLYB) Forecast

Analysts have given Rallybio Corp (RLYB) a Buy based on their latest research and market trends.

According to 6 analysts, Rallybio Corp (RLYB) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rallybio Corp (RLYB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.